Elinzanetant: Defining the Role of Dual Neurokinin-1 and Neurokinin-3 Receptor Antagonism for Management of Vasomotor Symptoms in Menopause.

Menopausal vasomotor symptoms (VMS) represent a significant public health burden, necessitating safe and effective nonhormonal treatments. The recent US Food and Drug Administration approval of elinzanetant, a first-in-class dual neurokinin-1 (NK1) and neurokinin-3 (NK3) receptor antagonist, represents a major shift and warrants a critical assessment of its role. VMS pathogenesis centers on the hypothalamic KNDy neuron network and is primarily mediated by Neurokinin B acting on the NK3 receptor. Elinzanetant's distinctive dual mechanism, simultaneously blocking NK3 (VMS control) and NK1 (mood and sleep modulation), translates into improved patient outcomes as demonstrated across the OASIS Phase 3 program. Specifically, elinzanetant achieved a 65.2%-67.0% reduction in VMS frequency by Week 12 (OASIS 1/2) and produced clinically meaningful improvement in the PROMIS SD-SF 8b sleep disturbance score. While indirect cross-over study comparisons with fezolinetant (NK3 antagonist) suggest a numerical advantage in sleep quality for elinzanetant, head-to-head trials are required for confirmation. The drug demonstrated sustained efficacy and a favorable long-term liver safety profile, making it strategically important for the general population. Elinzanetant represents a major shift in the nonhormonal treatment approach, offering a safe and sustained alternative for managing menopausal symptoms.